Takeda Pharmaceutical Company Ltd (TYO: 4502) and privately-held company Schrödinger Inc have formed a multi-target research collaboration that will align with Takeda's core therapeutic areas of interest, the Japanese company disclosed on Friday.

The collaboration combines Schrödinger's in silico platform-driven drug discovery capabilities with Takeda's expertise in structural biology and knowledge of therapeutic areas.

The multi-target discovery effort will be led by Schrödinger, with Takeda providing protein crystal structures. Schrödinger will use these with its computational platform to guide the design of new chemical entities.

The terms of the collaboration will see Takeda have the option to exclusively license the programmes from Schrödinger later in discovery at established economic terms. This will include pre-clinical, clinical and commercial milestones of up to USD170m per programme, as well as royalties on future sales.

Additional financial details were not disclosed.